UK-based Angle PLC is expecting to make a landmark regulatory submission to the US Food and Drug Administration early in the fourth quarter of 2019 for its liquid biopsy system.
Angle’s Parsortix device detects and captures circulating tumor cells (CTCs) in patients with cancer. The system is based on a...
Welcome to Medtech Insight
Create an account to read this article
Already a subscriber?